Elham Moases Ghaffary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elham Moases Ghaffary has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Omid Mirmosayyeb
Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, USA
8 shared publications - Vahid Shaygannejad
Isfahan University of Medical Sciences
5 shared publications - Saeed Vaheb
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 shared publications - Afshari-Safavi
Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran
3 shared publications - Mahdi Barzegar
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications - Mohammad Yazdan Panah
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications
Latest Publications
- 19 October 2026
- Published by Springer Nature in Neuropsychology Review
- p. 1-22
Cognitive Function and Disability in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis
- 19 October 2026
- Published by Springer Nature in Neuropsychology Review
- p. 1-22
Cognitive Function and Disability in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis
- Open Access
- 20 February 2026
- Published by AccScience Publishing in Advanced Neurology
- Vol. 5 (4) , 025440106
Tracking neurodegeneration in multiple sclerosis: the role of optical coherence tomography, optical coherence tomography angiography, and artificial intelligence-based imaging
Multiple sclerosis (MS) represents a chronic autoimmune disease involving the central nervous system through inflammation and progressive neurodegeneration. Monitoring disease progression, specifically in terms of neuroaxonal loss, has critical importance in guiding treatment and improving patient outcomes. This review discusses the evolving role of optical coherence tomography (OCT) and artificial intelligence (AI) in monitoring MS progression, highlighting their efficiency in assessing neuroaxonal damage, predicting disability, and complementing conventional imaging techniques. We synthesize current evidence on OCT and OCT angiography (OCTA) metrics, including peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell/inner plexiform layer (GCIPL) thickness, and their correlations with disability, cognitive impairment, magnetic resonance imaging (MRI) findings, and clinical progression. We further review machine learning and deep learning applications for OCT-based classification, segmentation, and prognosis in MS. Thinning of pRNFL and GCIPL correlates with higher expanded disability status scale, brain atrophy, and impaired cognition, often preceding clinical signs of progression. OCTA reveals reduced retinal capillary density in MS, supporting a vascular component in disease pathology. AI tools enhance OCT analysis through automated layer segmentation and predictive modeling, enabling individualized risk stratification and early detection of secondary progression. Multimodal AI frameworks that combine OCT with MRI and clinical data further enhance prognostic accuracy. In summary, OCT and AI are transforming MS disease progression tracking by providing affordable, non-invasive biomarkers reflecting neurodegeneration and cerebrovascular dysfunction. For achieving their full potential as predictive and therapeutic tools in individualized care for MS patients, standardization, external validation, and integration into clinical practice are essential.
- 20 February 2026
- Published by AccScience Publishing in Advanced Neurology
- Vol. 5 (4) , 025440106
Open AccessTracking neurodegeneration in multiple sclerosis: the role of optical coherence tomography, optical coherence tomography angiography, and artificial intelligence-based imaging
Multiple sclerosis (MS) represents a chronic autoimmune disease involving the central nervous system through inflammation and progressive neurodegeneration. Monitoring disease progression, specifically in terms of neuroaxonal loss, has critical importance in guiding treatment and improving patient outcomes. This review discusses the evolving role of optical coherence tomography (OCT) and artificial intelligence (AI) in monitoring MS progression, highlighting their efficiency in assessing neuroaxonal damage, predicting disability, and complementing conventional imaging techniques. We synthesize current evidence on OCT and OCT angiography (OCTA) metrics, including peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell/inner plexiform layer (GCIPL) thickness, and their correlations with disability, cognitive impairment, magnetic resonance imaging (MRI) findings, and clinical progression. We further review machine learning and deep learning applications for OCT-based classification, segmentation, and prognosis in MS. Thinning of pRNFL and GCIPL correlates with higher expanded disability status scale, brain atrophy, and impaired cognition, often preceding clinical signs of progression. OCTA reveals reduced retinal capillary density in MS, supporting a vascular component in disease pathology. AI tools enhance OCT analysis through automated layer segmentation and predictive modeling, enabling individualized risk stratification and early detection of secondary progression. Multimodal AI frameworks that combine OCT with MRI and clinical data further enhance prognostic accuracy. In summary, OCT and AI are transforming MS disease progression tracking by providing affordable, non-invasive biomarkers reflecting neurodegeneration and cerebrovascular dysfunction. For achieving their full potential as predictive and therapeutic tools in individualized care for MS patients, standardization, external validation, and integration into clinical practice are essential.
- Open Access
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.
Open AccessOral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.
- Open Access
- 1 January 2024
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2024 (1)
The Association of Salivary Cortisol Levels With Depression, Anxiety, and Quality of Life in Male Relapsing‐Remitting Multiple Sclerosis Patients: A Case‐Control Study
Background: Dysfunctions of the hypothalamic‐pituitary‐adrenal (HPA) axis can trigger multiple sclerosis (MS) symptoms. Mood disorders comorbid with MS are implicated in the HPA axis activation in most people with MS (pwMS). This study purposed to examine salivary cortisol (SC) levels and their association with mood disorders in pwMS. Methods: Forty‐three men as pwMS and sixteen men as healthy controls (HC) were included in this study. pwMS and HC completed the Beck Depression Inventory (BDI), 36‐Item Short Form Survey (SF‐36), Fatigue Severity Scale (FSS), Depression Anxiety and Stress Scale, and Hospital Anxiety and Depression Scale questionnaires. SC levels were also measured in pwMS and HC. A linear regression model was used to analyze the relationship between the Expanded Disability Status Scale (EDSS) and mood disorders and SC levels. Pearson’s or Spearman’s tests examined the correlation between SC levels and mood disorders. Results: The SC level, anxiety, depression, fatigue, and stress were significantly higher in pwMS than in HC ( p < 0.05). pwMS also showed significant correlations between SC levels and role physical ( r = 0.3, p < 0.05) and emotional ( r = 0.34, p < 0.05) in SF‐36. Among SF‐36 domains, only general health ( β = −0.72, p < 0.05) and physical functioning ( β = −1.61, p < 0.05) were negatively associated with disease duration. No correlation was found between SC levels and anxiety, depression, and fatigue ( p > 0.05). Conclusions: The pwMS showed mild to moderate depression, anxiety, and fatigue. Only general health and physical functioning as aspects of quality of life were related to disease duration, while SC levels, mood disorders, and other quality‐of‐life domains were not associated with clinical characteristics. Also, this study failed to find a significant role for SC as a valuable marker in approaching mood disorders in pwMS.
- 1 January 2024
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2024 (1)
Open AccessThe Association of Salivary Cortisol Levels With Depression, Anxiety, and Quality of Life in Male Relapsing‐Remitting Multiple Sclerosis Patients: A Case‐Control Study
Background: Dysfunctions of the hypothalamic‐pituitary‐adrenal (HPA) axis can trigger multiple sclerosis (MS) symptoms. Mood disorders comorbid with MS are implicated in the HPA axis activation in most people with MS (pwMS). This study purposed to examine salivary cortisol (SC) levels and their association with mood disorders in pwMS. Methods: Forty‐three men as pwMS and sixteen men as healthy controls (HC) were included in this study. pwMS and HC completed the Beck Depression Inventory (BDI), 36‐Item Short Form Survey (SF‐36), Fatigue Severity Scale (FSS), Depression Anxiety and Stress Scale, and Hospital Anxiety and Depression Scale questionnaires. SC levels were also measured in pwMS and HC. A linear regression model was used to analyze the relationship between the Expanded Disability Status Scale (EDSS) and mood disorders and SC levels. Pearson’s or Spearman’s tests examined the correlation between SC levels and mood disorders. Results: The SC level, anxiety, depression, fatigue, and stress were significantly higher in pwMS than in HC ( p < 0.05). pwMS also showed significant correlations between SC levels and role physical ( r = 0.3, p < 0.05) and emotional ( r = 0.34, p < 0.05) in SF‐36. Among SF‐36 domains, only general health ( β = −0.72, p < 0.05) and physical functioning ( β = −1.61, p < 0.05) were negatively associated with disease duration. No correlation was found between SC levels and anxiety, depression, and fatigue ( p > 0.05). Conclusions: The pwMS showed mild to moderate depression, anxiety, and fatigue. Only general health and physical functioning as aspects of quality of life were related to disease duration, while SC levels, mood disorders, and other quality‐of‐life domains were not associated with clinical characteristics. Also, this study failed to find a significant role for SC as a valuable marker in approaching mood disorders in pwMS.
- 18 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105191
Salivary Cortisol Levels and Its Associations with Depression, Anxiety, and Quality of Life Among Multiple Sclerosis Patients: A Case-Control Study
- 18 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105191
Salivary Cortisol Levels and Its Associations with Depression, Anxiety, and Quality of Life Among Multiple Sclerosis Patients: A Case-Control Study
- Open Access
- 29 November 2023
- Published by MDPI AG in Preprints.org
Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs have been developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.
- 29 November 2023
- Published by MDPI AG in Preprints.org
Open AccessOral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs have been developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.
- 6 February 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (6) , 1905-1915
Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis
Background Neuromyelitis optica spectrum disorder (NMOSD) is a progressive demyelinating disease of the central nervous system that has overlapping symptoms with multiple sclerosis (MS) but differs from it in a variety of ways. Previous studies have reported conflicting results trying to estimate the number of individuals affected by them which is why we designed this systematic review and meta-analysis to estimate the worldwide prevalence and incidence of NMOSD/NMO based on current evidence. Methods We searched PubMed, Scopus, EMBASE, Web of Science, and gray literature including references from the identified studies, review studies, and conference abstracts which were published up to February 1, 2022. We used all MeSH terms pertaining to “NMOSD,” “NMO,” and all the terms on “prevalence,” “incidence,” and “epidemiology” to identify the search components. Pooled effect sizes were measured using random-effect model by DerSimonian-Laird. Results The prevalence and incidence rates of NMOSD/NMO ranged from 0.07 to 10 and 0.029 to 0.880 per 100,000 population, respectively. The overall pooled prevalence of NMO per 100,000 population was 1.54 (I2: 98.4%, 95% CI: 1.13–1.96, P< 0.001) based on the 2006 criteria, 1.51 (I2: 99.4%, 95% CI: 1.21–1.81, P < 0.001) based on the 2015 criteria and 2.16 (I2: 89.4%, 95% CI: 1.46–2.86, P < 0.001) based on the 2006/2015 criteria. The overall annual incidence of NMO per 100,000 population was 0.155 (I2: 95%, 95% CI: 0.115–0.195, P < 0.001) based on the 2006 criteria and 0.278 (I2: 100%, 95% CI: 0.135–0.420, P < 0.001) based on the 2015 criteria. The prevalence rates were highest in French West Indies and South Korea, and lowest in Cuba and Australia, based on the 2006 and 2015 criteria, respectively. Also, the highest annual incidence rates were obtained for Sweden and Slovak republic and the lowest for Cuba and Australia based on the 2006 and 2015 criteria, respectively. All estimated rates were higher among females compared to males. Conclusion Although rare, NMOSD/NMO impact affected individuals in devastating ways. Several large-scale prospective studies are required to reach a comprehension of the epidemiological aspects of these notorious demyelinating conditions.
- 6 February 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (6) , 1905-1915
Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis
Background Neuromyelitis optica spectrum disorder (NMOSD) is a progressive demyelinating disease of the central nervous system that has overlapping symptoms with multiple sclerosis (MS) but differs from it in a variety of ways. Previous studies have reported conflicting results trying to estimate the number of individuals affected by them which is why we designed this systematic review and meta-analysis to estimate the worldwide prevalence and incidence of NMOSD/NMO based on current evidence. Methods We searched PubMed, Scopus, EMBASE, Web of Science, and gray literature including references from the identified studies, review studies, and conference abstracts which were published up to February 1, 2022. We used all MeSH terms pertaining to “NMOSD,” “NMO,” and all the terms on “prevalence,” “incidence,” and “epidemiology” to identify the search components. Pooled effect sizes were measured using random-effect model by DerSimonian-Laird. Results The prevalence and incidence rates of NMOSD/NMO ranged from 0.07 to 10 and 0.029 to 0.880 per 100,000 population, respectively. The overall pooled prevalence of NMO per 100,000 population was 1.54 (I2: 98.4%, 95% CI: 1.13–1.96, P< 0.001) based on the 2006 criteria, 1.51 (I2: 99.4%, 95% CI: 1.21–1.81, P < 0.001) based on the 2015 criteria and 2.16 (I2: 89.4%, 95% CI: 1.46–2.86, P < 0.001) based on the 2006/2015 criteria. The overall annual incidence of NMO per 100,000 population was 0.155 (I2: 95%, 95% CI: 0.115–0.195, P < 0.001) based on the 2006 criteria and 0.278 (I2: 100%, 95% CI: 0.135–0.420, P < 0.001) based on the 2015 criteria. The prevalence rates were highest in French West Indies and South Korea, and lowest in Cuba and Australia, based on the 2006 and 2015 criteria, respectively. Also, the highest annual incidence rates were obtained for Sweden and Slovak republic and the lowest for Cuba and Australia based on the 2006 and 2015 criteria, respectively. All estimated rates were higher among females compared to males. Conclusion Although rare, NMOSD/NMO impact affected individuals in devastating ways. Several large-scale prospective studies are required to reach a comprehension of the epidemiological aspects of these notorious demyelinating conditions.
- Open Access
- 17 September 2022
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-7
Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review
Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review: Background. Myasthenia gravis (MG) is a neuromuscular, autoimmune disease that causes weakness by impairing neuromuscular transmission. According to reports, vaccines can lead to autoimmunity in different ways, and COVID-19 vaccines are suggested to trigger MG. We conducted this systematic review to assess MG patients after the COVID-19 vaccination. Methods. We collected 231 studies from four databases from inception to 26 March 2022. Results. 4 case studies were selected from 231 research studies, and data were extracted based on inclusion criteria. In all cases, MG was reported following COVID-19 vaccination. Symptoms such as muscle weakness, numbness, and ptosis were common. The MG was confirmed through RNST, MRC, NCS, and AchR-binding antibody titer tests. Conclusion. Although all cases of MG were diagnosed following appropriate tests, the sample size was small; therefore, further investigation is required to demonstrate the possible association between MG and COVID-19 vaccination.
- 17 September 2022
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-7
Open AccessIs Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review
Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review: Background. Myasthenia gravis (MG) is a neuromuscular, autoimmune disease that causes weakness by impairing neuromuscular transmission. According to reports, vaccines can lead to autoimmunity in different ways, and COVID-19 vaccines are suggested to trigger MG. We conducted this systematic review to assess MG patients after the COVID-19 vaccination. Methods. We collected 231 studies from four databases from inception to 26 March 2022. Results. 4 case studies were selected from 231 research studies, and data were extracted based on inclusion criteria. In all cases, MG was reported following COVID-19 vaccination. Symptoms such as muscle weakness, numbness, and ptosis were common. The MG was confirmed through RNST, MRC, NCS, and AchR-binding antibody titer tests. Conclusion. Although all cases of MG were diagnosed following appropriate tests, the sample size was small; therefore, further investigation is required to demonstrate the possible association between MG and COVID-19 vaccination.
- 1 April 2020
- Published by Elsevier in Life Sciences
- Vol. 246, 117420
Immunomodulatory benefits of mesenchymal stem cells treated with Caffeine in adjuvant-induced arthritis
- 1 April 2020
- Published by Elsevier in Life Sciences
- Vol. 246, 117420
Immunomodulatory benefits of mesenchymal stem cells treated with Caffeine in adjuvant-induced arthritis